Abstract: An assay tray assembly and an assay tray primarily for chromatographic analysis has a plastics moulded test tray 1 mounted on a plastics moulded collection tray 72, The test tray has a spaced array of chambers 3 disposed as per a microtiter plate, Each chamber has a bottom outlet port 5 formed by a flange 8 which retains within the chamber a chromatographic medium to which test liquid deposited in the chamber is to be subjected for the percolate or eluate liquid to emerge from the respective outlet ports, The collection tray 72 has a spaced array of wells 16 disposed as per a microtiter plate to correspond with the chambers 3 and the tray 14 is mounted on the tray 72 for each chamber to communicate with a corresponding well 16. Each chamber 3 has a tubular spigot part 12 which extends into the respective well 16 to alleviate cross contamination of the liquid derived from the outlet ports 5.

Abstract: A solid phase coupling reagent for amide formation, comprising insoluble polymer bearing pendant side chains, said side chains each comprising a terminal portion having the formula ##STR1## wherein Y.sup.- is a counteranion and n is independently an integer from 2 to 6; and a method of making amides employing the coupling reagent.

Abstract: Antidepressant agents having the formula ##STR1## wherein R.sup.1 is a polycycloalkyl group; R.sup.2 is methyl or ethyl, X is O or NH; and Y comprises a 5- or 6-membered heterocyclic ring having one or two nitrogens; or fused bicyclic heterocyclic rings having a total of three nitrogen atoms, one in each ring and one angular nitrogen.

Abstract: Synthetic intermediates of 1-arylethyl-3-substituted piperidines.

Abstract: Compounds of the formula ##STR1## which are useful in treating migraine and other disorders, and intermediates used in the preparation of said compounds.

Abstract: Quinolone carboxylic acids of the formula ##STR1## wherein R.sup.1, R.sup.2, A and Y are as defined herein, and R.sup.3 is ##STR2## have antibacterial properties.

Abstract: Compounds of the formula ##STR1## wherein the broken line represents an optional double bond; X is O, S, CH.sub.2 or CH.sub.2 CH.sub.2, and the pharmaceutically acceptable salts thereof. The compounds are useful in treating inflammation or other prostaglandin or leukotriene mediated diseases.

Abstract: An acidic polycyclic ether antibiotic, having structure established by X-ray crystallography, is formed by fermentation of a novel microorganism, Actinomadura sp. ATCC 53764. This novel antibiotic is useful as an anticoccidial in chickens, in the prevention or treatment of swine dysentery, and as a growth promotant in cattle and swine.

Abstract: Compounds of the formula ##STR1## where R is alkyl, cycloalkyl, phenyl or substituted phenyl are useful as hypoglycemic agents.

Abstract: This invention relates to novel acidic polycyclic ether antibiotics CP-91,243 and CP-91,244 of the formula ##STR1## wherein R is H in CP-91,243 and R is CH.sub.3 in CP-91,244. The invention also relates to novel Actinomadura roseorufa microorganisms; processes for producing the novel antibiotics and the known antibiotic UK-58,852; methods for controlling coccidial infections in poultry, enteritis in livestock and swine dysentery; methods for promoting growth and/or improving efficiency of feed utilization in ruminant or monogastric animals; and nutrient feed compositions.This is a National filing under 35 U.S.C. 371 based on PCT/US89/02400 filed Jun. 1, 1989.

Abstract: A simplified method for making the chloromethyl ester of sulbactam in which the tetraalkylammonium sulbactam salt is not dried and isolated prior to alkylation. The method comprises reacting a tetraalkylammonium salt and a sulbactam salt in an aqueous solution to form an aqueous solution of tetraalkylammonium sulbactam. The tetraalkylammonium sulbactam is extracted into bromochloromethane or iodochloromethane, and water is removed from the organic layer to enhance the formation of the chloromethyl ester of sulbactam. The tetraalkylammonium sulbactam is reacted with bromochloromethane or iodochloromethane in the organic layer to form the chloromethyl ester of sulbactam.

Abstract: MUSCARINIC RECEPTOR ANTAGONISTS OF THE FOLLOWING FORMULAE: ##STR1## Muscarinic receptor antagonists, useful especially in the treatment of irritable bowel syndrome, of formula (IA) or (IB) or a pharmaceutically acceptable salt thereof, where R.sup.2 and R.sup.3 are each independently H, halo or C.sub.1 -C.sub.4 alkyl; m is 0, 1 or 2; n is 1, 2 or 3; Y is a direct link, O or S; with the proviso that when n is 1, Y is a direct link; Het is a group of formula (A) or (B), where p is 0, 1 or 2, q is 1, 2 or 3, and r is 0, 1, 2 or 3, with the proviso that the sum of p, q and r is at least 3, the N atom of "Het" being attached to the group (CH.sub.2).sub.n in formula (IA) and to the H atom in formula (IB); and R.sup.1 is a group of formula (a), (b) or Het.sup.1, where R.sup.4 and R.sup.5 are each independently H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, --(CH.sub.2).sub.t OH, halo, trifluoromethyl, cyano, --(CH.sub.2).sub.t NR.sup.6 R.sup.7, --CO(C.sub.1 -C.sub.4 alkyl), --OCO(C.sub.1 -C.sub.

Abstract: An optically active compound selected from the group consisting of a compound having the absolute stereochemical formula ##STR1## and a compound having the absolute stereochemical formula ##STR2## and intermediates thereof.

Abstract: The present invention relates to a method of treating or preventing emesis in mammals, including humans, using certain quinuclidine derivatives, piperidine derivatives, azanorbornane derivatives and related compounds.

Abstract: A transdermal flux enhancing pharmaceutical composition for transdermal administration to a human or lower animal subject comprising a safe and effective amount of a pharmacologically active compound or a prodrug thereof, an aqueous solvent system comprising from about 15 to 75% by volume of one or more water miscible solvents, and a penetration enhancer selected from certain 1-alkylazacycloheptan-2-ones and cis-olefin compounds of the formulaCH.sub.3 (CH.sub.2).sub.x CH.dbd.CH(CH.sub.2).sub.y R.sup.3where R.sup.3 is CH.sub.2 OH, CH.sub.2 NH.sub.2 or COR.sup.4 and R.sup.4 is OH or (C.sub.1 -C.sub.4)alkoxy, x and y are each an integer from 3 to 13 and the sum of x and y is from 10 to 16; methods for their use in treating various illnesses in a human or lower animal by transdermal administration of said composition.

Abstract: A method of lowering blood lipid levels, comprising administering to a patient in need of such treatment an effective amount of a compound of formula I ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is hydroxy or a group capable of being removed in vivo to produce a compound of formula I wherein R.sup.1 is OH; andX and Y are the same or different and are selected from hydrogen, trifluoromethyl, fluoro, and chloro.

Abstract: Quinolone carboxylic acids 7 -substituted by azabicyclo groups have antibacterial activity.

Abstract: A composition useful in the treatment of onychomycosis comprises tioconazole, a gel-forming agent and a hydro-alcoholic vehicle.

Abstract: 2-(8-Azabicyclo[3.2.1]oct-8-yl)alkanols of the formula ##STR1## wherein Q is S or CH.dbd.CH; X is H, OH or another aromatic substituent; R is hydrogen, alkyl, alkenyl or alkynyl; Y and Y.sup.1 are taken together and are arylmethylene or aralkylmethylene (or a corresponding epoxy derivative) or Y and Y.sup.1 are taken separately and Y is hydrogen or OH, and Y.sup.1 is aryl, aralkyl, arylthio, or aryloxy; and structurally related 2-(piperidino)alkanols; pharmaceutical compositions thereof; methods of treating CNS disorders therewith; and intermediates useful in the preparation of said compounds.

Abstract: Compounds of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X, m, n, o, p, q and r are as defined below. The compounds are memory enhancing cholinesterase inhibitors useful in enhancing memory, novel intermediates used in their synthesis, and analgesic agents.